gene

BCL2L1

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about BCL2L1: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

563Connections

1Hypotheses

2Analyses

50Outgoing

50Incoming

9Experiments

4Debates

Summary

BCL2L1 is a gene implicated in neurodegeneration research. Key relationships include: associated with, expressed in, regulates. Associated with ALS, Aging, Als. Connected to 302 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	BCL2L1
Chromosome	20q11.21
Protein Type	Signaling Protein
Target Class	Signaling Protein
Function	is a gene located on chromosome 20q11.21 that encodes a member of the BCL-2 family of proteins
Mechanism of Action	Small molecule inhibitor of anti-apoptotic protein function
Primary Expression	Cerebral cortex, Hippocampus, Substantia nigra, Spinal cord
Druggability	High (0.80)
Clinical Stage	Approved
Pathways	Akt, Nf-Κb, Pi3K, Toll-Like Receptor
UniProt ID	Q07817
NCBI Gene ID	598
Ensembl ID	ENSG00000171552
OMIM	300040
GeneCards	BCL2L1
Human Protein Atlas	BCL2L1
Associated Diseases	Als, Cancer, Carcinoma, Cardiovascular
Known Drugs/Compounds	Abt263, ABT263, rapamycin
Interactions	AGING, AKT, AMPK, AMYLOID, AND, APOPTOSIS
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	Senescent Microglia Resolution via Maresins-Senoly
KG Connections	563 knowledge graph edges
Databases	GeneCards HPA STRING

🔮 Predicted Structure: BCL2L1 — AlphaFold Q07817 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (7)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

flowchart TD
    FOXO["FOXO
Transcription Factor"] -->|"activates"| BCL2L1["BCL2L1
(Bcl-xL)
Anti-apoptotic Protein"]
    
    BCL2L1 -->|"inhibits"| Apoptosis["Cellular Apoptosis
Programmed Cell Death"]
    BCL2L1 -->|"regulates"| Mitochondria["Mitochondrial
Membrane Stability"]
    
    Apoptosis -->|"leads to"| Neurodegeneration["Neurodegeneration
Neural Cell Loss"]
    Mitochondria -->|"dysfunction causes"| Neurodegeneration
    
    BCL2L1 -->|"regulates"| Alzheimer["Alzheimer's Disease
Cognitive Decline"]
    BCL2L1 -->|"inhibits"| ALS["Amyotrophic Lateral
Sclerosis (ALS)"]
    BCL2L1 -->|"associated with"| Parkinson["Parkinson's Disease
Motor Dysfunction"]
    BCL2L1 -->|"associated with"| MS["Multiple Sclerosis
Demyelination"]
    
    BCL2L1 -->|"regulates"| Inflammation["Neuroinflammation
Immune Response"]
    BCL2L1 -->|"regulates"| Aging["Cellular Aging
Senescence"]
    BCL2L1 -->|"associated with"| Ischemia["Cerebral Ischemia
Oxygen Deprivation"]
    
    Inflammation -->|"contributes to"| Neurodegeneration
    Aging -->|"promotes"| Neurodegeneration
    Ischemia -->|"triggers"| Apoptosis
    
    BCL2L1 -->|"biomarker for"| Senescence["Cellular Senescence
Age-related Decline"]
    
    style BCL2L1 fill:#006494
    style FOXO fill:#4a1a6b
    style Apoptosis fill:#ef5350
    style Neurodegeneration fill:#5d4400
    style Mitochondria fill:#1b5e20
    style Inflammation fill:#ef5350
    style Aging fill:#5d4400
    style Senescence fill:#5d4400

Outgoing (421)

Target	Relation	Type	Str
Tumor Cell Survival	involved_in	process	0.93
EGFR-TKI Resistance	contributes_to	phenotype	0.92
Tumor Cell Survival	promotes	process	0.90
Egfr-Tki Resistance	contributes_to	phenotype	0.90
Egfr-Tki Resistance	upregulates	phenotype	0.90
Tumor Cell	expressed_in	cell_type	0.90
Apoptosis	inhibits	process	0.88
Apoptosis	associated_with	process	0.85
Biomarker For Egfr-Tki Resistance	biomarker_for	biomarker	0.85
Senescent Cells	involved_in	cell_type	0.85
apoptosis pathway	participates_in	pathway	0.80
SY-1365 Sensitivity	associated_with	phenotype	0.80
BCL-xL	encodes	protein	0.80
APOPTOSIS	upregulates	process	0.70
unfolded protein response	participates_in	pathway	0.70
EGFR-mutated lung cancer	associated_with	disease	0.70
neurodegeneration	associated_with	disease	0.66
Als	therapeutic_target	disease	0.65
Tumor	therapeutic_target	disease	0.65
Cancer	therapeutic_target	disease	0.65
Aging	regulates	disease	0.65
Ms	therapeutic_target	disease	0.65
Senescence	biomarker_for	disease	0.65
Obesity	regulates	disease	0.65
Als	regulates	disease	0.65
Inflammation	regulates	disease	0.65
Alzheimer	regulates	disease	0.65
Diabetes	regulates	disease	0.65
Neurodegeneration	regulates	disease	0.65
Cardiovascular	regulates	disease	0.65
Cancer	regulates	disease	0.65
ALS	regulates	disease	0.65
Cancer	associated_with	disease	0.65
Cardiovascular	associated_with	disease	0.65
Ischemia	associated_with	disease	0.65
Parkinson	associated_with	disease	0.65
Ms	associated_with	disease	0.65
Cancer	expressed_in	disease	0.65
Leukemia	inhibits	disease	0.65
Tumor	inhibits	disease	0.65
Als	inhibits	disease	0.65
Ms	interacts_with	disease	0.65
Cardiovascular	expressed_in	disease	0.65
Glioblastoma	inhibits	disease	0.65
Carcinoma	therapeutic_target	disease	0.65
Cancer	interacts_with	disease	0.65
Diabetes	expressed_in	disease	0.65
Als	associated_with	disease	0.65
Neurodegeneration	inhibits	disease	0.65
Als	activates	disease	0.65

Incoming (142)

Source	Relation	Type	Str
ABT263	inhibits	drug	0.95
EGFR-TKI Treatment	upregulates	drug	0.90
Abt263	inhibits	drug	0.90
h-3f02f222	targets	hypothesis	0.90
PD-1	downregulates	protein	0.82
PRV_gM	binds	protein	0.80
FOXO	activates	protein	0.80
TP53	regulates	gene	0.80
CASP3	interacts_with	gene	0.70
GABARAP	associated_with	gene	0.60
PIK3C3	associated_with	gene	0.60
MAP1LC3B	associated_with	gene	0.60
TFEB	associated_with	gene	0.60
MTOR	associated_with	gene	0.60
AMBRA1	associated_with	gene	0.60
CTSD	associated_with	gene	0.60
HDAC6	associated_with	gene	0.60
LAMP2	associated_with	gene	0.60
UVRAG	associated_with	gene	0.60
rapamycin	targets	drug	0.60
PI3K	activates	gene	0.60
EGFR	expressed_in	gene	0.60
APOPTOSIS	biomarker_for	gene	0.60
P16INK4A	biomarker_for	gene	0.60
ALZHEIMER	regulates	gene	0.60
P21CIP1	biomarker_for	gene	0.60
INFLAMMATION	regulates	gene	0.60
GENES	expressed_in	gene	0.60
CANCER	expressed_in	gene	0.60
RNA	associated_with	gene	0.60
GABA	associated_with	gene	0.60
BCL-2	expressed_in	gene	0.60
AR	activates	gene	0.60
AKT1	associated_with	gene	0.60
APP	interacts_with	gene	0.60
APP	targets	gene	0.60
GENES	activates	gene	0.60
AMPK	associated_with	gene	0.60
LC3B	associated_with	gene	0.60
ATG	associated_with	gene	0.60
OXIDATIVE STRESS	therapeutic_target	gene	0.60
NF-ΚB	regulates	gene	0.60
AGING	inhibits	gene	0.60
FERROPTOSIS	therapeutic_target	gene	0.60
CANCER	activates	gene	0.60
EGFR MUTATIONS	expressed_in	gene	0.60
APOPTOSIS	activates	gene	0.60
NF-ΚB	activates	gene	0.60
PRESENILIN	associated_with	gene	0.60
CANCER	associated_with	gene	0.60

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Senescent Microglia Resolution via Maresins-Senolytics Combi	0.784	neurodegeneration	Neuroinflammation resolution mechanisms

Mentioning Analyses (2)

Scientific analyses that reference this entity

Senescent cell clearance as neurodegeneration therapy

neurodegeneration | 2026-04-04 | 7 hypotheses Top: 1.000

Neuroinflammation resolution mechanisms and pro-resolving mediators

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.784

Experiments (9)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
Proposed experiment from debate on Senolytics targeting p16/p21+ senes	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$80,000
Mechanism: Why Does Amyloid Removal Only Slow Decline 27%?	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$7,500,000
cGAS-STING Pathway Validation Study in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$7,100,000
Microglial Aging and Immune Memory in Neurodegeneration — Training the	validation	Alzheimer's Disease	0.400	0.50	human	proposed	$2,960,000
Microglial Contributions to Huntington's Disease Pathogenesis	validation	Neuroinflammation	0.400	0.50	human	proposed	$2,960,000
Mixed Pathology Effects on Parkinson's Disease Progression and Treatme	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
NLRP3 Inflammasome Validation Study in Parkinson's Disease	clinical	Parkinson's Disease	0.400	0.50	human	proposed	$5,460,000
Senolytic Therapy (D+Q) Phase IIa Trial in Early Alzheimer's Disease	clinical	Alzheimer's Disease	0.400	0.50	human	proposed	$5,460,000
Traumatic Brain Injury and Alzheimer's Disease Relationship	validation	Alzheimer's Disease	0.400	0.50	human	proposed	$3,000,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Caloric Restriction Intervention Alters Specific Circulating Biomarkers of the S [PMID:37738560]	Justice JN, Leng XI, LeBrasseur NK, Tchk	J Gerontol A Biol Sci Med Sci	2024	1
Sex differences in autophagy-mediated diseases: toward precision medicine. [PMID:32264724]	Shang D, Wang L, Klionsky DJ, Cheng H, Z	Autophagy	2021	1
Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populatio [PMID:33144684]	He D, Wang D, Lu P, Yang N, Xue Z, Zhu X	Oncogene	2021	1
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells [PMID:26657143]	Chang J, Wang Y, Shao L, Laberge RM, Dem	Nat Med	2016	1
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs. [PMID:25754370]	Zhu Y, Tchkonia T, Pirtskhalava T, Gower	Aging Cell	2015	1
Senolytic elimination of therapy-induced senescent cells by ABT-263 improves che [PMID:41423036]	Zhang D, Zhu J, Zou R, Zhang H, Yu BP, L	Biochemical pharmacology	2026	0
Comprehensive assessment of the genomic stability of human induced pluripotent s [PMID:41877289]	Zhang K, Na T, Jia C, Yuan X, Guo M, Yan	Stem cell research & therapy	2026	0
Characterization of the Direct and Indirect Inhibition of Apoptosis by Full-Leng [PMID:41589352]	Elsner C, Epasto LM, Cieren A, Gendreizi	Chembiochem : a European journ	2026	0
Exploring the key molecular mechanisms and immune microenvironment of oxidative [PMID:41591671]	Cai Z, Li J, Li T, Peng Q	Discover oncology	2026	0
Navitoclax acts synergistically with irradiation to induce apoptosis in preclini [PMID:41430412]	Vardon A, Haston S, Hamdi H, Cooksley G,	Scientific reports	2025	0
Combination of senolytic and pro-resolving mediator shows synergistic benefit in [PMID:synthetic_19]	Unknown	Nat Aging	2024	0
Senolytic treatment diminishes microglia and decreases severity of experimental [PMID:39487537]	Drake SS, Zaman A, Gianfelice C, Hua EM,	Journal of neuroinflammation	2024	0
CSF markers of microglial senescence predict cognitive decline in Alzheimer's di [PMID:synthetic_20]	Unknown	Ann Neurol	2023	0
Senescent microglia accumulate in Alzheimer's disease brains and drive neuroinfl [PMID:synthetic_16]	Unknown	Nature	2023	0
Maresin 1 reprograms microglia from pro-inflammatory to phagocytic phenotype via [PMID:synthetic_17]	Unknown	Cell	2022	0
Senescent cells provide beneficial functions in tissue repair and immune surveil [PMID:synthetic_21]	Unknown	Nat Rev Immunol	2022	0
ABT-263 causes dose-limiting thrombocytopenia in cancer trials via BCL-xL inhibi [PMID:synthetic_22]	Unknown	J Clin Oncol	2020	0
The Beclin 1 network regulates autophagy and apoptosis. [PMID:21311563]	Kang R, Zeh HJ, Lotze MT, Tang D	Cell death and differentiation	2011	0
The landscape of somatic copy-number alteration across human cancers. [PMID:20164920]	Beroukhim R, Mermel CH, Porter D, Wei G,	Nature	2010	0
Serine/threonine protein phosphatases in apoptosis. [PMID:12127881]	Klumpp S, Krieglstein J	Current opinion in pharmacolog	2002	0

Debates (4)

Multi-agent debates referencing this entity

Related Research

Hypotheses and analyses mentioning BCL2L1 in their description or question text

No additional research found

BCL2L1

Understanding Entity Pages

Summary

Wiki Pages (7)

BCL2L1 Gene

BCL2L12 Gene

BCL2L10

BCL2L13

BCL2L1 Protein — BCL-XL

BCL2L11 Protein — BIM

Pathway Diagram

Outgoing (421)

Incoming (142)

Targeting Hypotheses (1)

Mentioning Analyses (2)

Senescent cell clearance as neurodegeneration therapy

Neuroinflammation resolution mechanisms and pro-resolving mediators

Experiments (9)

Related Papers (20)

Debates (4)

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

Investigate the therapeutic potential of clearing senescent cells (senolytics) t

SPMs (resolvins, protectins, maresins) from omega-3s may promote inflammation re

Senescent cell clearance as neurodegeneration therapy

Related Research

BCL2L1

Understanding Entity Pages

Summary

Wiki Pages (7)

BCL2L1 Gene

BCL2L12 Gene

BCL2L10

BCL2L13

BCL2L1 Protein — BCL-XL

BCL2L11 Protein — BIM

BCL2L11 Gene

Pathway Diagram

Outgoing (421)

Incoming (142)

Targeting Hypotheses (1)

Mentioning Analyses (2)

Senescent cell clearance as neurodegeneration therapy

Neuroinflammation resolution mechanisms and pro-resolving mediators

Experiments (9)

Related Papers (20)

Debates (4)

Should metabolic reprogramming via SIRT1/NAD+/PGC-1alpha axis be prioritized to

Investigate the therapeutic potential of clearing senescent cells (senolytics) t

SPMs (resolvins, protectins, maresins) from omega-3s may promote inflammation re

Senescent cell clearance as neurodegeneration therapy

Related Research